Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start [Yahoo! Finance]
Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference [Yahoo! Finance]
Forget Centessa Pharmaceuticals: This Rare-Disease Specialist Has a Superior Portfolio and Pipeline [Yahoo! Finance]
Centessa Pharmaceuticals (CNTA) was upgraded by Wolfe Research to "strong-buy".
Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $40.00 price target on the stock.